Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

Core Insights - Indivior Pharmaceuticals reported strong financial results for Q4 and full year 2025, with a focus on accelerating growth in 2026 through its Indivior Action Agenda [2][4][5] Financial Performance - Total SUBLOCADE net revenue reached $856 million for FY 2025, a 13% increase year-over-year, with Q4 2025 net revenue at $252 million, up 30% year-over-year [4][5][10] - GAAP net income for FY 2025 was $210 million, compared to $7 million in FY 2024, while non-GAAP net income was $320 million, up from $240 million [10][45] - Adjusted EBITDA for FY 2025 was $428 million, representing a 20% increase from FY 2024 [10][48] Business Strategy - The company has entered Phase II of the Indivior Action Agenda, focusing on accelerating SUBLOCADE growth and improving cash flow [2][4] - A new $400 million share repurchase program has been authorized to enhance shareholder value [4][5] Operational Highlights - U.S. SUBLOCADE net revenue increased by 13% to $794 million for FY 2025, driven by a 7% growth in dispense unit volume [5][31] - A nationwide direct-to-consumer campaign was launched to raise awareness of SUBLOCADE and long-acting injectables for opioid use disorder [5][12] Future Guidance - For FY 2026, the company expects total net revenue between $1,125 million and $1,195 million, with SUBLOCADE net revenue projected between $905 million and $945 million [6][7] - Operating expenses are expected to be managed within $430 million to $450 million, with adjusted EBITDA anticipated between $535 million and $575 million [6][7]